header

Jack West's NSCLC Briefing is the first product listed on Endpoints Exchange — a curated biotech research platform where authors can sell high-quality new research directly to the market.

Upon purchase, you'll receive an informative new report with key insights into current care practices in lung cancer. Then on April 16, you'll have same-day access to Dr. West's analysis on Phase III readouts at AACR 2018 of PD-1/PD-L1 combinations in 1L NSCLC from Merck, Bristol-Myers, and Roche.

Endpoints Exchange was launched in partnership with biotech expert Brad Loncar. Inspiration for the idea came from our shared belief that top-shelf research deserves to be accessible to all. It shouldn’t be influenced by banking relationships, nor should distribution be kept to a tight circle of well-connected investors. We teamed up with Loncar on a platform that changes that. Now foundations, academic researchers, companies with no banking needs, and investors regardless of affiliation have a new independent option.

Jack West's NSCLC Briefing

1 instant download of PDF report &
2 access to April 16 mid-day call with Dr. West.

$5,000 Buy Now

Two-part briefing includes:


1


New report on immunotherapy in current practices
How are oncologists treating 1L NSCLC? Dr. West just polled twenty of his practicing peers — 10 lung cancer specialists and 10 general oncologists — and is now publishing his findings in a PDF report, available for instant download upon purchase.


Immunotherapy in Locally Advanced & Metastatic NSCLC

You will learn in this report:

  • Where KOLs and general oncologists converge and differ on immunotherapy in the management of lung cancer?
  • How does each group extrapolate trial data to patients falling outside narrow trial requirements?
  • How do they weigh 1L therapy and later options for advanced NSCLC by histology, PD-L1 status, presence of a driver mutation, and potentially use of tumor mutation burden?
  • What do oncologists project to be the leading approaches in the near future, and beyond?
Survey Details

Survey Questions

The survey was conducted in early March 2018 of 20 currently practicing oncologists in the United States. Dr. Jack West wrote the questions, posed them to his peers, and then wrote the definitive analysis of current care practices for 1L NSCLC.

Sample figures

— and —

2


April 16 conference call with Dr. West
Live mid-day from AACR in Chicago, jump on an exclusive conference call with Dr. West for his instant analysis on the data presented.



On this call Dr. West will:

  • Give his immediate takeaways after attending AACR session on Phase III PD-1/PD-L1 combinations in 1L NSCLC from Merck, Bristol-Myers, and Roche.
  • Discuss PFS data comparison between the three competing studies ( KEYNOTE-189, CheckMate-227, and IMpower150 ) and if Merck's OS data could be differentiating.
  • ... and more.

Purchase briefing

Are you an Endpoints News email subscriber?

I'm already a subscriber Register a free account

Purchase as a guest

Quick Guest Purchase
← Go back
← Go back
We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Terms & Conditions
  • Payment and billing instructions
    Upfront payment via credit card required. Immediate service and download if you purchase using an Endpoints account. If you want to purchase as a guest, or if you require prior invoicing, click here. Once paid via credit card, you'll be emailed the report and added to the conference call. No refunds for any reason.
  • One license per purchase
    No sharing is allowed and you are limited to 5 downloads of the PDF report. For multiple copies or group purchases, please contact us with the blue button in the lower right for quick service.
  • How to access the briefing
    Once paid, you will be presented with a download link to the PDF report and an email will be sent with conference call details.
  • This is not investment advice
    Endpoints Exchange is not an investment advisor. Nothing on this platform should be understood as recommendation to enter in any securities transactions or to engage in any manner of investment strategies.
  • Not an editorial product
    Written, produced, and owned by H. Jack West, and sold through the Endpoints Exchange platform. No editors from Endpoints News were involved in the creation of this product.
  • No warranty or representations
    While Endpoints Exchange authors endeavor to make sure the information is accurate and reliable, Endpoints makes no warranties or representations as to the accuracy, correctness, reliability or otherwise with respect to the products sold on its platform, and assumes no liability or responsibility for any omissions or errors in the content available on this site.

About


Endpoints Exchange is helping democratize institutional research by creating a place where premium expertise can be published and purchased by all. Access to great biotech research shouldn't depend on the right banking or corporate relationships. And experts with significant new reports should have a direct way to publish and market to the right audiences without giving up the farm to traditional distribution channels.

The Endpoints Company is exclusively partnered with biotech expert Brad Loncar on Endpoints Exchange to solve these issues.

Contact
Arsalan Arif
@AKAarsalan

Brad Loncar
@BradLoncar



Key Facts


One report at a time
We're focused on high impact work, not quantity. When a report is featured on Endpoints Exchange, you can be sure it's exclusive and worthy of your attention. And it'll only be available for a limited time.
Author owned
All content is owned by the expert and sold turn-key on the platform, with Endpoints charging a flat percentage service fee.

Interesting in selling your research on Endpoints Exchange? Contact us.

On April 16 at AACR, lung cancer treatment is set to change. Dr. Jack West has created an exclusive two-part research product to help you prepare.

Act now. Opportunity ends April 15 ->
Endpoints Exchange